Bristol Myers Squibb vs Novo Nordisk A S
Bristol Myers Squibb and Novo Nordisk A S are similar in size: $48.19bn and $46.82bn of revenue in their latest fiscal years. Novo Nordisk A S grew faster (11.1% against -0.2%). Novo Nordisk A S kept more of each dollar of sales as profit: a net margin of 33.1% against 14.6%. Novo Nordisk A S carries less debt relative to equity (136.1% against 254.9%).
| Latest fiscal year | Bristol Myers SquibbBMY, 2025 | Novo Nordisk A SNVO, 2025 |
|---|---|---|
| Revenue | $48.19bn | $46.82bn |
| Revenue growth | -0.2% | 11.1% |
| Net income | $7.05bn | $15.52bn |
| Operating margin | — | 41.3% |
| Net margin | 14.6% | 33.1% |
| Return on equity | 40.5% | 61.6% |
| Free cash flow | $12.85bn | $8.93bn |
| Cash | $10.21bn | $4.16bn |
| Total debt | $47.09bn | $41.49bn |
| Debt to equity | 254.9% | 136.1% |
| Dividend per share | $2.49 | — |
| Dividend yield | 4.0% | 4.4% |
| Share buybacks | $0 | $210m |
| Employees | 32,500 | — |
| Market value | $126.73bn | $177.65bn |
| Price vs our value range | Below our value range | Below our value range |
| Moat score | 77 (Strong) | — |
| Insider trades, 12 months | 0 buys, 4 sales | 0 buys, 0 sales |